Alteogen Inc.
196170
Rangering i aksjer
#1844
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Aksjekurs
$165.61
Markedsverdi
$11.53B
Endring (1 dag)
4.13%
Endring (1 år)
-46.48%
Land
KR
Handel Alteogen Inc. (196170)
Kategori
Healthcare
Antall utestående aksjer for Alteogen Inc. (196170)
Antall utestående aksjer per June 2026: 73.51M
Ifølge Alteogen Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 73.51M. Ved slutten av December 2023 hadde selskapet 51.66M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Alteogen Inc. (196170) fra 2012 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 73.51M | 38.40% |
| 2024 | 53.12M | 2.82% |
| 2023 | 51.66M | 0.74% |
| 2022 | 51.28M | -15.57% |
| 2021 | 60.74M | 20.48% |
| 2020 | 50.41M | 4.62% |
| 2019 | 48.19M | 5.97% |
| 2018 | 45.47M | 1.22% |
| 2017 | 44.92M | 3.62% |
| 2016 | 43.36M | 2.60% |
| 2015 | 42.26M | 34.26% |
| 2014 | 31.48M | 64.68% |
| 2013 | 19.11M | 15.04% |
| 2012 | 16.61M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 245.39% |
US
|
|
| 396.00M | 438.69% |
US
|
|
| 478.91M | 551.48% |
AU
|
|
| 62.19M | -15.41% |
NL
|
|
| - | - |
CH
|
